Global Apheresis Market Analysis

Global Apheresis Market Executive Summary

The Global apheresis market size is at around $3.6 Bn in 2022 and is projected to reach $6.4 Bn in 2030, exhibiting a CAGR of 8% during the forecast period. According to a prediction by the Economist Intelligence Unit (EIU), global healthcare spending would increase by just 4.9% in 2023, which won't amount to a substantial increase in spending because of high inflation and poor economic development. According to a poll of international medical insurers done by WTW (NASDAQ: WTW), widespread inflation and rising healthcare demand are combining to push expected rises in global healthcare benefit costs to their highest level in over 15 years. According to the 2023 Global Medical Trends Survey, healthcare benefit cost trends increased from 8.2% in 2021 to an unexpectedly high 8.8% in 2022, and they are expected to continue to rise in 2023 to a stubbornly high global average of 10%. Numerous regions will be affected by the cost trend rises, such as Latin America, where average increases are anticipated to rise from 18.2% to 18.9%, Asia Pacific by 6.9% to 10.2%, and the Middle East and Africa from 10.5% to 11.5%.

Apheresis is the extraction of whole blood from a patient or donor. Whole blood's constituent parts are separated in a device that is essentially a centrifuge. The remaining components are then re-transfused into the patient or donor while one of the separated pieces is withheld. The components that are separated and removed include leukocytes (leukapheresis), platelets (plateletpheresis), and plasma (plasmapheresis). Toxins and other hazardous substances in the blood can potentially be reduced with apheresis. When used therapeutically, the apheresis method is customized with regard to the number of treatments, the amount of blood or other components to be removed, and the kind of solution used to replace the lost volume. Some of the diseases that benefit from apheresis are myasthenia gravis, Goodpasture's syndrome, familial hypercholesterolemia, systemic lupus with life-threatening complications, etc.

Similar to plasma exchange and plasma adsorption, apheresis therapy is becoming a useful therapeutic option in critical care. Apheresis therapy is routinely administered to patients in intensive care units with sepsis, autoimmune illness, haemolytic uraemic syndrome, and thrombotic thrombocytopenic purpura. Patients who require artificial liver support and have fulminant hepatic failure can also benefit from apheresis therapy. Complication rates vary and range from 4% to 36%, but the majority of incidents are minor and easily manageable. The estimated fatality rate is 3 per 10,000 procedures, and the majority of recorded deaths in severely ill patients have been attributable to cardiac and pulmonary problems. Because calcium ions from the infusion chelate citrate ions in the anticoagulants, symptomatic hypocalcaemia is the most frequent side effect of apheresis. The pseudocholinesterase required for the metabolism of some drugs as well as coagulation inhibitors is some of the chemicals that are removed by apheresis. The removal of coagulation inhibitors may make individuals more susceptible to thrombosis.

Market Dynamics

Market Growth Drivers

Various chronic disorders increase the chance of organ failure in patients. Such severe organ failure situations necessitate organ transplant operations. Due to the rise in the prevalence of chronic diseases, more of these surgeries are anticipated in the upcoming years. In response, it is predicted that during the forecast period, the Global apheresis market will grow as the demand for blood and blood products increases.

Market Restraints

Despite the rising demand for blood and its products, some people are reluctant to donate blood, which causes a shortage of blood in the facilities thereby slowing down the Global apheresis market expansion. Furthermore, the Global apheresis market growth is limited by the high cost of apheresis devices and therapeutic apheresis techniques.

Competitive Landscape

Key Players

• Fresenius Kabi
• Terumo
• Haemonetics
• Macopharma
• Scinomed
• Nigale
• B-Braun

Healthcare Policies and Regulatory Landscape

1. Food and Drug Administration (FDA): The FDA is a regulatory body within the Department of Health and Human Services that oversees the safety and effectiveness of apheresis equipment in the US
2. European Medicines Agency (EMA): The EMA, a regulatory body of the European Union (EU), is in charge of supervising monitoring, and evaluating the safety of apheresis equipment in the EU
3. International Organization for Standardization (ISO): The ISO is a non-governmental organization that develops and disseminates global standards for several industries, including the manufacturing of medical equipment. The ISO has released a number of standards pertaining to apheresis equipment, such as ISO 13958:2014, which offers instructions on the clinical application of apheresis equipment